histologically confirmed solid malignancy with metastatic disease detected on imaging.
Conditions
Interventions
Group 1: SBRT and systemic therapy will be applied as clinically indicated . Patients’ imaging data (clinical routine) and blood samples (study-specific) will be prospectively collected.
Sponsors
Universitätsklinikum Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • histologically confirmed solid malignancy with metastatic disease detected on imaging. Biopsy confirmation of metastatic disease is preferred but not required • one to ten extracranial active tumor lesions on recent imaging • local radiotherapy is clinically indicated and scheduled according to one of the INTERACT schemes • ECOG 0/1 • age =18 years • able and willing to provide informed consent
Exclusion criteria
Exclusion criteria: • serious medical comorbidities precluding ablative radiotherapy • substantial overlap of disease sites with a previously treated radiation volume that precludes meeting dose constraints in a composite plan • malignant meningitis • pregnant or lactating individuals • patient’s refusal to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The registry's objectives include descriptive analysis of outcomes after SBRT and enrichment of the analyses of the planned randomized arms in the planned, randomized INTERACT Trial. Translational studies include radiomics and liquid biomarkers. | — |
Secondary
| Measure | Time frame |
|---|---|
| The registry's objectives include descriptive analysis of outcomes after SBRT and enrichment of the analyses of the planned randomized arms in the planned, randomized INTERACT Trial. Translational studies include radiomics and liquid biomarkers. | — |
Countries
Germany
Contacts
Public ContactThomas Held
Universitätsklinikum Heidelberg
Outcome results
None listed